menu search

Bristol myers (bmy) uc candidate fails in phase ii study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to...

October 8, 2021, 10:20 am

Bristol myers (bmy) uc candidate fails in phase ii study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to...

October 8, 2021, 10:20 am

Bristol myers (bmy) uc candidate fails in phase ii study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to...

October 8, 2021, 10:20 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...

October 8, 2021, 1:00 am

Bristol myers' tyk2 inhibitor disappoints in mid-stage ulcerative colitis study

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to...

October 7, 2021, 10:23 am

Bristol myers' tyk2 inhibitor disappoints in mid-stage ulcerative colitis study

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to...

October 7, 2021, 10:23 am

Bristol myers' tyk2 inhibitor disappoints in mid-stage ulcerative colitis study

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to...

October 7, 2021, 10:23 am

Timber pharmaceuticals reports positive top-line results from phase 2b control study evaluating tmb-001 in moderate to severe congenital ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America...

October 7, 2021, 9:11 am

Timber pharmaceuticals reports positive top-line results from phase 2b control study evaluating tmb-001 in moderate to severe congenital ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America...

October 7, 2021, 9:11 am

Timber pharmaceuticals reports positive top-line results from phase 2b control study evaluating tmb-001 in moderate to severe congenital ichthyosis

Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE America...

October 7, 2021, 9:11 am

Short sainsbury's says jp morgan as ultrafast delivery poses serious threat

Ultrafast grocery delivery is becoming an increasing threat to the established grocery giants according to JP Morgan, which recommends shorting (sell)...

October 7, 2021, 7:47 am

Short sainsbury's says jp morgan as ultrafast delivery poses serious threat

Ultrafast grocery delivery is becoming an increasing threat to the established grocery giants according to JP Morgan, which recommends shorting (sell)...

October 7, 2021, 7:47 am

Short sainsbury's says jp morgan as ultrafast delivery poses serious threat

Ultrafast grocery delivery is becoming an increasing threat to the established grocery giants according to JP Morgan, which recommends shorting (sell)...

October 7, 2021, 7:47 am

Oil volatility shows how difficult it is for value investors in cyclical sectors

Over the past decade, oil markets have experienced some of the most severe conditions ever seen by one ...

October 6, 2021, 3:17 pm

Oil volatility shows how difficult it is for value investors in cyclical sectors

Over the past decade, oil markets have experienced some of the most severe conditions ever seen by one ...

October 6, 2021, 3:17 pm

Oil volatility shows how difficult it is for value investors in cyclical sectors

Over the past decade, oil markets have experienced some of the most severe conditions ever seen by one ...

October 6, 2021, 3:17 pm

Aim immunotech moving forward to develop ampligen as intranasal coronavirus treatment as it publishes phase i safety data

AIM ImmunoTech Inc (NYSE:AIM) reported that a Phase 1 clinical study of Ampligen as an intranasal treatment for coronavirus (COVID-19) had shown "no...

October 6, 2021, 8:41 am


Search within

Pages Search Results: